Nektar Therapeutics
NKTR
176 hedge funds and large institutions have $1.91B invested in Nektar Therapeutics in 2016 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 70 increasing their positions, 61 reducing their positions, and 24 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
28% more call options, than puts
Call options by funds: $3.72M | Put options by funds: $2.9M
15% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 61
0.5% less ownership
Funds ownership: 102.61% → 102.11% (-0.5%)
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
2% less funds holding
Funds holding: 179 → 176 (-3)
19% less capital invested
Capital invested by funds: $2.35B → $1.91B (-$437M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$40.7M |
| 2 |
BM
Bridger Management
New York
|
+$25M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$15.8M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$12.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$94.3M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$26.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$5.46M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$5.31M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$4.15M |
NKTR Hedge Fund Activity: Q1 2016 in Review
176 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2016, worth a combined $1.91B — down 19% from $2.35B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of NKTR and 23 opened new positions — a net loss of 1 holder — while 61 trimmed existing stakes and 70 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $40.7M. The largest seller was First Trust Advisors, cutting an estimated $94.3M.
- 176 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2016, down from 179 in Q4 2015.
- Funds reported $1.91B of Nektar Therapeutics stock for Q1 2016, down 19% quarter-over-quarter.
- 23 funds opened new Nektar Therapeutics positions in Q1 2016 and 24 closed out, a net change of -1 holder.
- The largest Nektar Therapeutics buyer in Q1 2016 was RA Capital Management, an estimated $40.7M added.
- The largest Nektar Therapeutics seller in Q1 2016 was First Trust Advisors, an estimated $94.3M sold.
Based on aggregated 13F filings for Q1 2016.